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ORIGINAL ARTICLES: ENDOMETRIOSISAssessing brain-derived
neurotrophic factor as a novel
clinical marker of endometriosis
Jocelyn M. Wessels, Ph.D.,a Vanessa R. Kay, B.Sc.,a Nicholas A. Leyland, M.D.,a Sanjay K. Agarwal, M.D.,b
and Warren G. Foster, Ph.D.a
a Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada; and b Department of
Reproductive Medicine, University of California, San Diego, La Jolla, CaliforniaObjective: To evaluate novel clinical markers of endometriosis including the neurotrophins brain-derived neurotrophic factor (BDNF),
nerve growth factor (NGF), and neurotrophin 4/5 (NT4/5) and compare them to others previously reported in the literature including
cancer antigen 125 (CA-125) and C-reactive protein (CRP).
Design: Prospective study.
Setting: University hospital.
Patient(s): One hundred thirty-eight women were prospectively and consecutively recruited (April 2011–April 2015; cases:
undergoing endometriosis surgery, n ¼ 96; controls: benign gynecological surgery, n ¼ 24 combined with healthy women, no
history of pelvic pain, not undergoing surgery, n ¼ 18).
Intervention(s): Collection of peripheral blood, gynecological and demographic information, eutopic biopsy in women undergoing
laparoscopy.
Main Outcome Measure(s): Circulating BDNF, NGF, NT4/5, CA-125, and CRP were quantiﬁed by ELISA.
Result(s): Plasma concentrations of BDNF were signiﬁcantly greater in women with endometriosis (1,091.9 pg/mL [640.4–1,683.1];
n ¼ 68, untreated) than in controls (731.4 pg/mL [352.1–1,176.2]; n ¼ 36), whereas circulating NGF, NT4/5, CA-125, and CRP were
not different. When assessed for their ability to differentiate between women with revised Classiﬁcation of the American Society of
Reproductive Medicine stage 1 and 2 or stage 3 and 4 disease and controls, BDNF was the only putative marker able to identify stage
1 and 2 disease, with a sensitivity and speciﬁcity of 91.7% and 69.4%, respectively, using an arbitrary cutoff value of 1,000 pg/mL.
We also demonstrated that circulating BDNF in women with endometriosis who were receiving ovarian suppression for disease was
equivalent to that in the control group. This suggests that BDNF may also offer the opportunity to monitor patient response to treatment.
Conclusion(s): Plasma BDNF is a potentially useful clinical marker of endometriosis that is superior to NGF, NT4/5, CA-125, and CRP.Use your smartphone
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ORIGINAL ARTICLE: ENDOMETRIOSIS$1.8 billion in Canada (10). Signiﬁcantly more resources are
spent on endometriosis than on other chronic conditions
(migraines, asthma, and Crohn's disease) (8), and thus
identiﬁcation of a clinical marker of disease remains a top
priority.
Emerging evidence suggests an important role for the
neurotrophins, a family of growth factors including
brain-derived neurotrophic factor (BDNF), nerve growth factor
(NGF), neurotrophin 3, (NT-3), and neurotrophin 4/5 (NT4/5),
in uterine physiology (11, 12) and endometrial pathology
(13–17). Results of a small study suggest that women with
endometriosis have elevated circulating BDNF concentrations
compared with healthy controls, which decreased after
surgical removal of lesions (18). However, this study was
limited to patients with stage 1 and 2 disease only, and
controls were healthy women alone. Moreover, the prior
study was limited to BDNF, and thus it is unknown how well
BDNF would compare to other clinical markers in this
population. Subsequently, protein expression for BDNF and
its high afﬁnity receptor were found to be greater in the
uterus of women with endometriosis compared with in
disease-free controls (13, 16). Therefore, the objectives of this
prospective case-control study were to assess the suitability
of circulating concentrations of neurotrophins including
BDNF, NGF, and NT4/5 as independent clinical markers of
endometriosis and to contrast our results with other putative
clinical markers of endometriosis including cancer antigen
125 (CA-125) and C-reactive protein (CRP) in the same popu-
lation of women. Herein we present the results of our interim
analysis of the study data.MATERIALS AND METHODS
Study Participants
One hundred thirty-eight women were recruited and screened
for inclusion in the study (Supplemental Fig. 1). One hundred
twenty women undergoing gynecological laparoscopy be-
tween April 2011 and April 2015 for pelvic pain thought to
be due to endometriosis were prospectively and consecutively
recruited. Of these, 96 were found to have endometriosis
(cases, n ¼ 96) and 24 were diagnosed with other benign
gynecological conditions (symptomatic controls, n ¼ 24).
Eighteen womenwith no history of pelvic pain and not under-
going surgery were also recruited (asymptomatic controls, n
¼ 18). The study exclusion criteria were individuals unable
to provide consent, age under 18, pregnancy, or a diagnosis
of adenomyosis in the control group (three of 138). Adeno-
myosis was diagnosed by the gynecological surgeon using
pelvic ultrasound and surgical evidence of disease. Women
receiving hormone therapies for endometriosis in the
3 months before study enrollment were excluded from the un-
treated group of cases but were included in the treated group
of cases (Supplemental Fig. 1) to determine the effect of
endometriosis treatment on circulating clinical markers. All
participants completed demographics and gynecologic ques-
tionnaires from which menstrual cycle length, date of last
menstruation, and pelvic pain were determined. Pelvic pain
was assessed using a nonstandardized pelvic pain test con-
sisting of four separate 5-point questions on a visual analog120scale and totaled out of 20. Menstrual cycle stage was deter-
mined by uterine biopsy for women undergoing surgery and
using the date of last menstruation for those not undergoing
surgery. During laparoscopic surgery women were catego-
rized as a case or symptomatic control by a gynecological sur-
geon, and the diagnoses were conﬁrmed by pathology reports.
The stage of endometriosis was determined by the surgeon
during surgery according to the revised Classiﬁcation of the
American Society of Reproductive Medicine (rAFS) (19).
This study was approved by the Research Ethics Board,
McMaster University (Institutional Review Board no. 06-
064, 14-066-T), and all participants provided written
informed consent before surgery.
Peripheral blood was collected from participants into
plasma and serum separator tubes (BD Canada) by a nurse
at McMaster University Medical Centre. As our initial primary
markers/endpoints are found in plasma, serum was not
collected from most asymptomatic controls (n ¼ 16) nor
from a few other cases (n ¼ 11). Blood was placed on ice,
transferred to the laboratory, and centrifuged at 3,000 rpm,
and approximately 200 mL of plasma or serum was aliquoted
into 1.8 mL cryovials (Sarstedt) and frozen at 80C.BDNF Assay
Plasma samples were thawed at room temperature, and BDNF
concentrations were quantiﬁed in triplicate using the BDNF
Emax immunoassay ELISA (Promega) following the manu-
facturer's protocol. Brieﬂy, 96-well NUNC maxisorp plates
(Fisher Scientiﬁc) were coated with antihuman BDNF anti-
body overnight. Freshly thawed plasma samples were diluted
1:10 with the provided sample buffer. After incubation, the
absorbance was read at 450 nm within 30 minutes using the
Biotek Synergy spectrophotometer (Fisher Scientiﬁc). The
kit sensitivity was 15.6 pg/mL.NGF and NT4/5 Assays
Serum samples were thawed at room temperature, and circu-
lating NGF was quantiﬁed in duplicate in neat serum using
the human b-NGF Mini ELISA Development Kit (Peprotech)
following the manufacturer's protocol. Incubations for
the sample and detection antibody were lengthened to 3
and 2.5 hours, respectively. The kit has a sensitivity of 16
pg/mL. NT4/5 was quantiﬁed in duplicate using the
Human NT-4 ELISA (RayBiotech), which has a sensitivity of
2 pg/mL. The plates were incubated with neat serum overnight
at 4C and according to the manufacturer's protocol. ELISAs
were read as above.CA-125 and CRP Assays
Circulating CA-125 and CRP were quantiﬁed in duplicate us-
ing the Human CA-125/MUC16 Quantikine ELISA Kit (R&D
Systems) and Human CRP ELISA (Life Technologies),
following the manufacturers' protocols. Plasma samples
were thawed at room temperature and diluted 1:3 (CA-125)
or 1:4,000 (CRP) with the diluent provided. The sensitivity
of the CA-125 and CRP assays is 0.035 U/mL and 10 pg/mL,
respectively. ELISAs were read as above.VOL. 105 NO. 1 / JANUARY 2016
TABLE 1
Patient characteristics of women with and without endometriosis.
Characteristic
Control
(n[ 36)
Case
(n[ 93)
P
value
Age (y), mean  SD 29.9  8.5 34.7  7.0 .001
Ethnicity, n (%)
Caucasian 28 (78) 68 (73) .004
Asian 7 (19) 4 (4)
Black 0 (0) 5 (5)
Unknown 1 (3) 16 (17)
Occupational status, n (%)
Employed 16 (44) 53 (57) .017
Unemployed 1 (3) 1 (1)
Other 15 (42) 12 (13)
Unknown 4 (11) 27 (29)
Smoking status, n (%)
Nonsmoker 34 (94) 70 (75) .031
Smoker, <20 cigarettes/d 2 (6) 10 (11)
Unknown 0 (0) 13 (14)
Median age at ﬁrst
menstruation, y
(25%–75%)
12 (12–13) 12 (11–13) .639
Median duration of
bleeding, d (25%–75%)
6 (5–7) 6 (4–7) .817
Menstrual cycle stage, n (%)
Menstrual 5 (14) 13 (14)
Proliferative 9 (25) 19 (20) .348
Secretory 12 (33) 20 (22)
Unknown 2 (6) 16 (17)
Ovarian suppression 8 (22) 25 (27)
Median pelvic pain
(self-report, 0–20)
(25%–75%)
3 (2–8) 9 (6–11) < .001
Current medical therapies,
n (%)
Hormonal contraceptives 8 (22) 9 (10) .176
Lupron 0 (0) 16 (17)
Nonsteroidal anti-
inﬂammatory drug
2 (5) 15 (16)
Narcotic analgesic 1 (3) 6 (6)
None/other 25 (70) 47 (51)
Stage of endometriosis,
n (%)
Minimal, 1 0 (0) 10 (11) NA
Mild, 2 0 (0) 9 (10)
Moderate, 3 0 (0) 10 (11)
Severe, 4 0 (0) 64 (68)
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Fertility and Sterility®Data and Statistical Analysis
Before our study, we anticipated a difference in circulating
BDNF between cases and controls of approximately 250 pg/
mL and an SD of plasma BDNF concentrations of 230 pg/
mL, on the basis of our preliminary results and those of Gian-
nini et al. (18). Sample size was calculated to be 15 women per
group, using the two-tailed Student's t-test, with a power of
80% and alpha of 5%. The sample size calculation to detect
differences in plasma BDNF across disease stage (control vs.
stage 1 and 2 vs. stage 3 and 4) by analysis of variance was
calculated to be 18 women per group, using the same param-
eters as above. Patient demographics were compared between
cases and controls by t-test, Mann-Whitney rank sum test, or
c2 (SigmaStat 3.5 Systat Software) and are presented in
Table 1 as mean  SD, median (25%–75% percentiles) or n,
%. For demographics that differed signiﬁcantly between cases
and controls, multiple logistic regression was carried out to
determine whether any of the factors were signiﬁcantly asso-
ciated with being classiﬁed as a case or control. Nine women
were excluded from the study owing to missing samples (n ¼
2), nondetectable BDNF (n ¼ 1), or a diagnosis of adenomyo-
sis (n ¼ 3), or they were classiﬁed as a control but taking Lu-
pron (n ¼ 3). After determining that there was no signiﬁcant
difference in circulating BDNF between asymptomatic
women who were (n ¼ 6) and were not (n ¼ 12) on oral con-
traceptives (Supplemental Fig. 2A; P¼ .174), we combined
them to increase the sample size of the control group. Symp-
tomatic controls who were (n ¼ 2) and were not (n ¼ 16) on
oral contraceptives were also combined (Supplemental
Fig. 2B; P¼ .663).
Next, the concentrations of BDNF, CA-125, and CRP were
compared between the symptomatic and asymptomatic con-
trol groups (Supplemental Fig. 2C, 2D, 2E, respectively) by
t-test or Mann-Whitney rank sum test and did not differ
signiﬁcantly (P¼ .159, .950, .137, respectively). Therefore,
the two control groups (symptomatic and asymptomatic)
were combined into one control group for all subsequent an-
alyses. Circulating BDNF, NGF, NT4/5, CA-125, and CRP con-
centrations were compared by Mann-Whitney rank sum test
(cases [all stages] vs. controls), or Kruskal-Wallis one-way
analysis of variance on ranks (across stage of disease and
by treatment) using SigmaStat (Systat Software Inc.) and
are presented in the text as medians (25%–75% percentile).
Receiver operating characteristic (ROC) curves were compiled
for circulating BDNF, NGF, NT4/5, CA-125, and CRP using the
ROC macro in SigmaStat. P< .05 was considered statistically
signiﬁcant.
RESULTS
Patient Characteristics
Of the women recruited to participate in this study (n ¼ 138),
120 underwent laparoscopic surgery from which 96 cases of
endometriosis and 24 symptomatic controls (women experi-
encing pain due to other indications including pelvic pain
no diagnostic abnormality [n¼ 3], benign cysts [n¼ 4], uter-
ine ﬁbroids [n ¼ 5], adenomyosis [excluded, n ¼ 3], chronic
inﬂammation [n ¼ 3], polycystic ovary syndrome [n ¼ 3],
endometrial polyps [n ¼ 1], or epidermoid cyst [n ¼ 2])VOL. 105 NO. 1 / JANUARY 2016were identiﬁed. Three women in the control group were
receiving Lupron and were thus excluded from the study (di-
agnoses: polycystic ovary syndrome [n ¼ 1], ﬁbroids [n ¼ 1],
chronic inﬂammation [n¼ 1]). An additional group of women
with no history of pelvic pain (asymptomatic) not undergoing
surgery were recruited as healthy controls (n ¼ 18). After the
exclusion of women with adenomyosis (n ¼ 3), controls on
Lupron (n ¼ 3), the removal of incomplete samples (n ¼ 2),
nondetects (n ¼ 1), and amalgamation of control groups,
the ﬁnal study population was 129 women: 93 cases and 36
controls (Supplemental Fig. 1).
The average age of cases was signiﬁcantly higher
(P¼ .001) than that of controls (34.7  7.0 vs. 29.9  8.5,
respectively; Table 1), and ethnicity (P¼ .004), occupational
status (P¼ .017), and smoking status (P¼ .031) differed be-
tween cases and controls. Self-reported pelvic pain was
signiﬁcantly higher in cases than in controls (three of 20 vs.121
ORIGINAL ARTICLE: ENDOMETRIOSISnine of 20; P%.001). Multiple logistic regression analysis was
conducted using the designation of ‘‘case’’ or ‘‘control’’ as the
dependent variable and age, ethnicity, occupational status,
smoking status, and pain as independent variables to deter-
mine their effect on the dependent variable. In this model,
only pain (P< .001) remained signiﬁcantly associated with
being a case or control, while age (P¼ .055), ethnicity
(P¼ .265), occupational status (P¼ .461), and smoking status
(P¼ .879) were not.
Menstrual cycle stage, current medical therapies, age at
ﬁrst menstruation (12 [11–13] years for cases vs. 12 [12–13]
years for controls; P¼ .639), and duration of bleeding in
days (6 [4–7] for cases vs. 6 [5–7] for controls: P¼ .817)
were not different between groups. Of the 93 cases, 68 had
not received any hormone treatment in the 3 months before
surgery (21 were using nonsteroidal anti-inﬂammatory drugs
[NSAIDs] or narcotic analgesics to manage pain), and 25 were
being treated for endometriosis (hormonal contraceptives
[nine of 25] and Lupron [16 of 25]).Neurotrophins, CA-125, CRP, and Endometriosis
Our data set was analyzed separately (univariate analysis) for
each putative marker, ﬁrst regardless of stage of disease or
menstrual cycle stage. The median circulating concentration
of BDNF in the plasma was signiﬁcantly greater (P¼ .018)
in women with endometriosis (1,091.9 [640.4–1,683.1] pg/
mL; n ¼ 68, untreated) than in controls (731.4 [352.1–
1,176.2] pg/mL; n¼ 36; Fig. 1A). To determine whether circu-
lating concentrations of BDNF, NGF, NT4/5, CA-125, and CRP
were affected by menstrual cycle phase, the data were reana-
lyzed by phase (menstrual, proliferative, secretory) in un-
treated cases (Supplemental Fig. 3A–3D). The effect of
menstrual cycle on circulating BDNF was also assessed in un-
treated controls (Supplemental Fig. 3F). There was no signif-
icant effect of menstrual cycle phase on circulating BDNF
(P¼ .648), NGF (P¼ .169), NT4/5 (P¼ .314), CA-125
(P¼ .821), or CRP (P¼ .360) in untreated cases and no signif-
icant effect of cycle phase on circulating BDNF in controls
(P¼ .460). Thus subsequent analyses were not stratiﬁed by cy-
cle stage. Further, as pelvic pain had been found to be signif-
icantly associated with being a case or control in our
preliminary statistical analysis, the relationship between pel-
vic pain and each putative biomarker was determined by
linear regression in untreated cases and controls. No signiﬁ-
cant association with pelvic pain was observed for BDNF
(P¼ .307), NGF (P¼ .687), CA-125 (P¼ .613), or CRP
(P¼ .152; Supplemental Fig. 4A, 4B, 4D, 4E, respectively).
However, NT4/5 was signiﬁcantly associated with pain
(P¼ .012; Supplemental Fig. 4C). As the majority of markers
did not have an association with pain, subsequent analyses
were not stratiﬁed by pelvic pain. Finally, no association be-
tween circulating BDNF and age was observed using linear
regression in cases and controls (Supplemental Fig. 4F).
Serum samples were unavailable for asymptomatic
women and 11 cases. However, circulating NGF in the serum
of the remaining subset of untreated cases (n ¼ 57) was 71.1
(29.7–173.4) pg/mL and was not signiﬁcantly different
(P¼ .418) from a subset of controls (n ¼ 22) who had concen-122trations of 77.9 pg/mL (28.5–99.2 pg/mL; Fig. 1B). In the same
subset, the median circulating NT4/5 in the serum was 7.9
(3.8–20.1) pg/mL, which did not differ signiﬁcantly
(P¼ .351) compared to women without endometriosis who
had 5.2 pg/mL (0.3–24.0 pg/mL; Fig. 1C).
In women with endometriosis (n ¼ 68, untreated), the
circulating concentration of CA-125 in the plasma was 7.8
(4.0–18.9) U/mL and was not signiﬁcantly different
(P¼ .369) from that of women without endometriosis (n ¼
36) who had concentrations of 7.0 U/mL (5.1–10.5 U/mL;
Fig. 1D). In the same group of women, circulating CRP did
not differ (P¼ .929) between cases (2.2 [0.6–4.6] mg/mL) and
controls (3.1 [0.5–3.8] mg/mL; Fig. 1E).Neurotrophins, CA-125, CRP, and Stage of Disease
The relationship between circulating BDNF, NGF, NT4/5, CA-
125, and CRP and stage of disease in women not receiving
treatment for endometriosis (Fig. 2) was determined. Women
with stage 1 and 2 endometriosis had signiﬁcantly elevated
BDNF (P¼ .028) compared with controls (1,178.6 [1,043.8–
1,433.8] pg/mL vs. 731.4 [352.1–1,176.2] pg/mL, respectively;
stage 1 and 2, n ¼ 12; controls, n ¼ 36; Fig. 2A). No signiﬁ-
cant difference in circulating BDNF was found for
women with stage 1 and 2 versus stage 3 and 4 (1,178.6
[1,043.8–1,433.8] pg/mL stage 1 and 2, n ¼ 12; vs. 1,076
[593.7–1,433.8] pg/mL stage 3 and 4; n ¼ 56, respectively)
nor between women with stage 3 and 4 disease versus the
control group (1,076 [593.7–1,433.8] pg/mL vs. 731.4
[352.1–1,176.2] pg/mL, respectively). NGF (Fig. 2B) and
NT4/5 (Fig. 2C) were compared across stage of disease and
did not differ signiﬁcantly (P¼ .619 and .463; respectively).
Circulating CA-125was signiﬁcantly increased in women
with stage 3 and 4 endometriosis versus women with stage 1
and 2 disease (P¼ .007; 9.2 [4.8–21.7] U/mL vs. 3.7 [2.5–7.3]
U/mL; n ¼ 56 and 12, respectively; Fig. 2D). There were no
signiﬁcant differences between women with stage 1 and 2
or stage 3 and 4 disease and controls. Nor were signiﬁcant dif-
ferences in CRP observed between women with stage 1 and 2
or 3 and 4 disease and controls (3.8 [0.9–4.6 ], 1.8 [0.6–4.6],
and 3.1 [0.5–3.8] mg/mL, respectively; P¼ .638; Fig. 2E).
ROC curves for BDNF, NGF, NT4/5, CA-125, and CRP
were generated including women with stage 1 and 2 disease
(n ¼ 12) who were not receiving endometriosis treatment
compared with controls (Fig. 2F). BDNF had the greatest
area under the curve (0.75; P¼ .009) compared with NGF
(0.54; P¼ .76), NT4/5 (0.49; P¼1.04), CA-125 (0.27;
P¼1.98), and CRP (0.59; P¼ .34). Using an arbitrary cutoff
value of 1,000 pg/mL, the sensitivity and speciﬁcity of
BDNF as a biomarker of stage 1 and 2 disease were 91.7%
(conﬁdence interval [CI], 61.5%–99.8%) and 69.4% (CI,
51.9%–83.7%), respectively.Neurotrophins, CA-125, CRP, and Endometriosis
Treatment
The effect of treatment on circulating levels of putative endo-
metriosis biomarkers was assessed (Fig. 3). The treated group
of women had stage 1 and 2 (seven of 25) and stage 3 and 4VOL. 105 NO. 1 / JANUARY 2016
FIGURE 1
Putative biomarkers of endometriosis. The circulating concentration of BDNF in the plasma was signiﬁcantly elevated (P¼.018) in women with all
stages of endometriosis whowere not receiving hormone treatment or Lupron (n¼ 68) comparedwith womenwithout endometriosis (n¼ 36) (A).
Neither circulating NGF (B) nor NT4/5 (C) differed signiﬁcantly between a subgroup of cases (n¼ 57) and controls (n¼ 22). Circulating CA-125 (D)
and CRP (E) were quantiﬁed in the same women as BDNF. Neither CA-125 nor CRP differed between cases and controls. Statistically signiﬁcant
differences are denoted by an asterisk (*) above the graph. Whiskers on the box plots represent the 10th and 90th percentiles, while the lower
limit of the box is the 25th percentile and the upper limit is the 75th percentile. The line within the box is the median of the data. Dots below
or above the box plots are the 5th and 95th percentiles, respectively.
Wessels. BDNF as a clinical marker of endometriosis. Fertil Steril 2016.
Fertility and Sterility®(18 of 25) disease, and treatments included oral contracep-
tives (nine of 25) and Lupron (16 of 25). No signiﬁcant differ-
ence (P¼ .203) in the concentration of BDNF was observed
between women on oral contraceptives and those on Lupron
(Supplemental Fig. 5), thus they were grouped together and
called the ‘‘treated’’ group in all subsequent analyses. Women
in the untreated group (n¼ 68) were not receiving endometri-
osis treatment (47 of 68) or were only using NSAIDs (15 of 68)
or narcotic analgesics (six of 68) to manage pain. The un-VOL. 105 NO. 1 / JANUARY 2016treated group consisted of women in stage 1 and 2 (12 of
68) and stage 3 and 4 (56 of 68). Of the ﬁve putative markers
quantiﬁed, only BDNF (Fig. 3A) demonstrated a signiﬁcant
difference between untreated and treated women with endo-
metriosis and controls (1,091.9 [640.4–1,683.1] vs. 729.1
[439.7–1,488.2] vs. 731.4 [352.1–1,176.2] pg/mL, respec-
tively; P¼ .025). No signiﬁcant difference in circulating
BDNF was observed between women treated for endometri-
osis and controls (P¼ .971). There was no effect of treatment123
FIGURE 2
Neurotrophins, CA-125, CRP, and stage of disease. Women with stage 1 and 2 endometriosis (n ¼ 12) who were not receiving treatment had
signiﬁcantly elevated BDNF (P¼.028) as compared with controls (n ¼ 36) (A). There were no signiﬁcant differences between women with stage
1 and 2 versus stage 3 and 4 disease (n ¼ 56) nor between women with stage 3 and 4 disease versus controls. No signiﬁcant difference in
circulating NGF (B) nor NT4/5 (C) was observed between groups in a subset (control ¼ 22; stage 1 and 2 ¼ 9; stage 3 and 4 ¼ 48). Circulating
CA-125 was signiﬁcantly increased (P¼.007) in women with stage 3 and 4 endometriosis as compared with those with stage 1 and 2 disease
(D). No signiﬁcant difference in CRP was seen between women with stage 1 and 2 or those with stage 3 and 4 disease and controls (E). ROC
curves for BDNF, NGF, NT4/5, CA-125, and CRP were generated for women with stage 1 and 2 disease not receiving treatment for
endometriosis (stage 1 and 2; n ¼ 12) versus controls (n ¼ 36) (F), and BDNF had the greatest area (A) under the curve (0.75; P¼.009)
compared with NGF (0.54; P¼.76), NT4/5 (0.49; P¼1.04), CA-125 (0.27; P¼1.98), and CRP (0.59; P¼.34). Using an arbitrary cutoff value of
1,000 pg/mL, the sensitivity and speciﬁcity of BDNF as a biomarker of stage 1 and 2 disease were 91.7% (CI, 61.5%–99.8%) and 69.4% (CI,
51.9%–83.7%), respectively. Statistically signiﬁcant differences are denoted by an asterisk (*) above the graph. Whiskers on the box plots
represent the 10th and 90th percentiles, while the lower limit of the box is the 25th percentile and the upper limit is the 75th percentile. The
line within the box is the median of the data. Dots below or above the box plots are the 5th and 95th percentiles, respectively.
Wessels. BDNF as a clinical marker of endometriosis. Fertil Steril 2016.
ORIGINAL ARTICLE: ENDOMETRIOSISon circulating concentrations of NGF (71.1 [29.7–173.4] vs.
103.8 [70.6–346.1] vs. 77.9 [28.5–99.2] pg/mL; P¼ .060;
Fig. 3B), NT4/5 (7.6 [3.8–20.0] vs. 3.5 [0.7–37.9] vs. 5.2124[0.3–24.0] pg/mL; P¼ .395; Fig. 3C), CA-125 (7.8 [4.0–18.8]
vs. 8.3 [5.7–11.5] vs. 7.0 [5.1–10.5] U/mL; P¼ .634; Fig. 3D),
or CRP (2.2 [0.6–4.6] vs. 2.6 [1.5–3.8] vs. 3.1 [0.5–3.8] mg/VOL. 105 NO. 1 / JANUARY 2016
FIGURE 3
Neurotrophins, CA-125, CRP, and endometriosis treatment. Women in the untreated group (n ¼ 68) were not receiving endometriosis treatment,
whereas those in the treated group (n ¼ 25) were on oral contraceptives or Lupron. Circulating BDNF (A) was signiﬁcantly elevated (P¼.025) in
women with endometriosis who were not receiving treatment compared with women receiving treatment and controls (n ¼ 36). There was no
signiﬁcant difference in NGF (B), NT4/5 (C), CA-125 (D), or CRP (E) across the groups. Statistically signiﬁcant differences are denoted by an
asterisk (*) above the graph. Whiskers on the box plots represent the 10th and 90th percentiles, while the lower limit of the box is the 25th
percentile and the upper limit is the 75th percentile. The line within the box is the median of the data. Dots below or above the box plots are
the 5th and 95th percentiles, respectively.
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Fertility and Sterility®mL; P¼ .898; Fig. 3E) among untreated, treated, and control
women, respectively.DISCUSSION
The results of the present study reveal that plasma BDNF
concentrations are greater in the circulation of women
with endometriosis, particularly those with stage 1 and 2 dis-VOL. 105 NO. 1 / JANUARY 2016ease, compared with in a control group consisting of symp-
tomatic (women with pelvic pain but not endometriosis) and
asymptomatic (healthy) women. Moreover, we demonstrated
that employing BDNF as a biomarker of stage 1 and 2 disease
using an arbitrary cutoff value of 1,000 pg/mL resulted in a
test with high sensitivity 91.7% (CI, 61.5%–99.8%) and an
acceptable speciﬁcity 69.4% (CI, 51.9%–83.7%). We also
show that CA-125 is signiﬁcantly elevated in women with125
ORIGINAL ARTICLE: ENDOMETRIOSISstage 3 and 4 endometriosis versus in women with stage 1
and 2 disease.
In this study we sought to compare BDNF to other neu-
rotrophins including NGF and NT/4/5 and other previously
studied putative markers of endometriosis CA-125 and
CRP (20–22) as a single, relatively noninvasive marker of
endometriosis. CA-125 was selected as a comparator
because it is the most studied marker of endometriosis
(20), and CRP was selected owing to its association with
inﬂammation (20). A panel including all biomarkers com-
bined was assessed by multiple logistic regression analysis
(data not shown), however, univariate analysis of BDNF
proved a better predictor of disease. The inclusion of
BDNF in a panel consisting of endometriosis biomarkers
other than those presented in this study is warranted and
might increase the ability of a panel to detect stage 1 and
2 disease. Furthermore, our results suggest that rather than
developing one panel of biomarkers to predict all stages of
endometriosis, a separate panel for stages 1 and 2 and stages
3 and 4 might increase their sensitivity and speciﬁcity. Of
the ﬁve putative markers described, BDNF was superior
owing to its ability to detect rAFS stage 1 and 2 disease,
which is often difﬁcult to diagnose clinically, and because
it was lower in women receiving ovarian suppressive thera-
pies for endometriosis (oral contraceptives and Lupron) than
in untreated women. Although not directly assessed in this
study, monitoring BDNF before and during endometriosis
treatment might show a relationship with treatment efﬁcacy
and provide a proxy of patient response to treatment.
Overall, we found that circulating concentrations of
BDNF were signiﬁcantly higher in women with endometri-
osis who were not receiving treatment versus in the control
group. We also observed that circulating BDNF was lower in
women receiving ovarian suppression to treat endometriosis
as compared with untreated women. We acknowledge that it
is ideal to include a 3-month hormone-free treatment period
before study enrollment to eliminate the potential con-
founding effects of ovarian suppression. However, we sug-
gest that the inclusion of a group of treated cases in the
present study is an accurate reﬂection of the clinical reality.
Our results are in accordance with and expand upon the
ﬁndings of a prior study (18), which showed a signiﬁcant
elevation in plasma BDNF in women with stage 1 and 2 dis-
ease versus healthy controls and a decrease in concentration
after surgical removal of lesions. However, the previous
study did not explore the relationship between circulating
BDNF in women with endometriosis compared with women
with pelvic pain but without endometriosis (symptomatic
controls), did not include women with stage 3 and 4 disease,
and did not include women receiving medical therapies.
Another larger study of fertility patients revealed a link be-
tween the presence of a BDNF (Met) single-nucleotide poly-
morphism (SNP) and increased severity of endometriosis
(stages 3 and 4), which was thought to contribute to
endometriosis-associated infertility (17). On the basis of
our results indicating that BDNF is elevated in stage 1 and
2 disease, we hypothesize that the circulating concentration
of BDNF might more accurately reﬂect disease activity
(number of red/black lesions). This would, perhaps in part,126explain the large variation in circulating BDNF in women
with stage 3 and 4 disease, where adhesions and inactive le-
sions often predominate. Furthermore, an SNP in the BDNF
gene was previously reported (17) and was associated with
an increased severity of endometriosis. On the basis of our
hypothesis that BDNF relates to the activity of disease,
perhaps the SNP increased the number of active lesions
and thus the severity of the disease. Taken together, several
studies have now identiﬁed a link between BDNF and
endometriosis.
We propose that an ideal clinical marker of endometri-
osis would be measurable in blood, sensitive and speciﬁc in
identifying patients with all stages of the disease, and
decrease in response to medical and surgical therapies. Our
results revealed that, of all the markers studied, only plasma
BDNF concentrations were higher in untreated cases than in
treated cases. Although both BDNF and NT4/5 had previ-
ously been shown to be overexpressed in the eutopic endo-
metrium of women with endometriosis versus controls (16),
serum NT4/5 levels were not different between cases and
controls in the present study. Thus, we propose that
although neurotrophin family members are potentially
important in the pathophysiology of endometriosis, only
plasma BDNF shows promise as a novel clinical marker of
endometriosis. Moreover, our results suggest that measure-
ment of plasma BDNF may have value as a marker of treat-
ment response in patients with endometriosis. We suggest
that a prospective analysis of circulating BDNF in untreated
women with endometriosis seeking treatment should be un-
dertaken along with validated pain and quality-of-life ques-
tionnaires to address the utility of BDNF as a marker of
patient response to treatment.
The strengths of our study include the prospective case-
control design, conﬁrmation of endometriosis diagnosis by
surgery and pathology, inclusion of a treated group of
women with endometriosis, and assessment of potential
confounders (pain, age, menstrual cycle phase, ethnicity,
occupation, and smoking status). We also consider the in-
clusion of a clinically relevant control group (symptomatic)
as a strength of the study. Upon initial analysis, these
women were not different from healthy asymptomatic con-
trols, and thus they were merged into a single control group
for subsequent analyses. Additionally, our study examined
the effect of menstrual cycle phase on the putative bio-
markers quantiﬁed, even though many biomarker studies
do not take menstrual cycle stage into consideration during
study design and/or analysis (22). In our cohort of untreated
women, there was no effect of menstrual cycle phase, as
determined by endometrial biopsy, on any of the putative
markers quantiﬁed. Other studies have found an effect of
menstrual cycle phase on endometriosis markers, in partic-
ular the elevated ratio of serum CA-125 between menses
and the proliferative phase was demonstrated to be
increased in women with endometriosis as compared with
controls (23–25) and has been proposed as a putative
biomarker. However, because CA-125 did not differ across
cycle phases in our cohort, comparison of BDNF as a clinical
marker against the CA-125 menses to the proliferative phase
ratio could not be done. Furthermore, two studies in healthyVOL. 105 NO. 1 / JANUARY 2016
Fertility and Sterility®cycling women found a signiﬁcant increase in circulating
BDNF during the secretory phase (days 20–24) as compared
with during the proliferative phase (days 6–8) (26, 27).
However, we did not observe any difference in BDNF
concentration, nor any other putative marker quantiﬁed,
between phases of the menstrual cycle in our study
population.
Divergent study results are likely explained by the fact
that women were not recruited on speciﬁc cycle days into
our study, as they had been in other studies describing an
effect of menstrual cycle stage, and all samples were
collected in the morning, thus avoiding diurnal variation
in plasma BDNF as previously reported (24). As there was
no difference between cycle phases, our data were not strat-
iﬁed by cycle phase. By grouping women as cases or con-
trols and not subdividing by menstrual cycle phase we
were likely biasing our results toward the null hypothesis,
that there was no difference in circulating concentrations
of BDNF between groups. However, we observed signiﬁ-
cantly greater BDNF concentrations in women with endo-
metriosis than in those without, validating our decision
not to stratify our data and further suggesting that the dif-
ference in concentrations might in fact be widened by using
more rigorous inclusion and analysis criteria in future
studies. Furthermore, the ability to quantify BDNF on any
cycle day is an advantage for a clinical marker, as it can
be quantiﬁed on the day a woman presents to the clinic
and not delayed.
Although the results of the present study are encouraging,
there are a number of important limitations. Speciﬁcally, as a
tertiary care center for endometriosis, the majority of our pa-
tient population presents with advanced-stage disease and
thus the sample size for stage 1 and 2 endometriosis is limited.
Since there is generally little rationale to operate on women
with stage 1 and 2 disease, we are restricted to incidental ﬁnd-
ings of endometriosis in women undergoing laparoscopy for
other indications.
Another potential limitation is that our asymptomatic
controls did not undergo surgery to rule out a diagnosis of
endometriosis. However, if any of the asymptomatic controls
were to have endometriosis, our results would be biased to-
ward the null hypothesis, that no difference in circulating
BDNF exists between womenwith andwithout endometriosis.
Thus, we are conﬁdent in including these women in our study.
Finally, the results of this study pertain to a particular study
population, and thus our results need to be independently
validated to add external validity.
In conclusion, plasma BDNF is superior to NGF, NT4/5,
CA-125, and CRP in our cohort of women as a single, rela-
tively noninvasive clinical marker of endometriosis. Further,
BDNF has promising sensitivity 91.7% and speciﬁcity 69.4%
for detecting stage 1 and 2 endometriosis and may also
provide an indicator of patient response to treatment.
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SUPPLEMENTAL FIGURE 1
Study design. One hundred thirty-eight women were prospectively and consecutively recruited to participate in the study. Gynecological
laparoscopy was performed on 120 women, from which a group of 96 women with endometriosis and 24 women with other diagnoses
(symptomatic controls) were derived. An additional 18 healthy women who were not undergoing surgery were recruited as asymptomatic
controls. After the exclusion of women with adenomyosis (n ¼ 3), controls on Lupron (n ¼ 3), the removal of incomplete samples (n ¼ 2),
nondetects (n ¼ 1), and amalgamation of control groups, the ﬁnal study population was 129 women: 93 cases and 36 controls. Of the 93
cases, 68 women were not receiving treatment for endometriosis or were only managing their pain symptoms with NSAIDs or narcotic
analgesics, while 25 were receiving treatment for endometriosis including oral contraceptives and Lupron. The putative biomarkers of
endometriosis were statistically compared between the symptomatic and asymptomatic controls and did not differ. Thus, the control groups
were combined (n ¼ 36) for all subsequent analyses.
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SUPPLEMENTAL FIGURE 2
Amalgamation of asymptomatic and symptomatic control groups. Asymptomatic women who were (n ¼ 6) and were not (n ¼ 12) on oral
contraceptives did not have a statistically signiﬁcant difference (P¼.174) in circulating BDNF (A). Thus, they were combined to increase the
sample size of the control group. Symptomatic controls who were (n ¼ 2) and were not (n ¼ 16) on oral contraceptives were also combined
because there was no signiﬁcant difference in circulating BDNF (P¼.663) (B). Circulating concentrations of BDNF (C), CA-125 (D), and CRP (E)
were compared between the symptomatic and asymptomatic control groups and did not differ signiﬁcantly (P¼.159, .950, and .137,
respectively). The two control groups (symptomatic and asymptomatic) were combined into one control group for all subsequent analyses.
Whiskers on the box plots represent the 10th and 90th percentiles, while the lower limit of the box is the 25th percentile and the upper limit is
the 75th percentile. The line within the box is the median of the data.
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SUPPLEMENTAL FIGURE 3
Effect of menstrual cycle phase on putative clinical markers. The effect of menstrual cycle phase on the concentration of circulating biomarkers in
untreated cases (A–E) and controls (F) was assessed. There were no signiﬁcant differences in BDNF (P¼.648) (A), NGF (P¼.169) (B), NT4/5 (P¼.314)
(C), CA-125 (P¼.821) (D), or CRP (P¼.360) (E) across the cycle phases in our study sample of women. Nor was there a signiﬁcant difference in
circulating BDNF across menstrual cycle phase in the controls (P¼.460) (F). Thus subsequent analyses were not stratiﬁed by cycle stage.
Whiskers on the box plots represent the 10th and 90th percentiles, while the lower limit of the box is the 25th percentile and the upper limit is
the 75th percentile. The line within the box is the median of the data. Dots below or above the box plots are the 5th and 95th percentiles,
respectively.
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SUPPLEMENTAL FIGURE 4
Effect of pelvic pain and age on putative clinical markers. The relationship between pelvic pain and each putative biomarker was determined by
linear regression using pain as the dependent variable in untreated cases and controls. No signiﬁcant association was observed for BDNF (n ¼
92; P¼.307) (A), NGF (n ¼ 78; P¼.687) (B), CA-125 (n ¼ 92; P¼.613) (D), or CRP (n ¼ 92; P¼.152) (E). There was a signiﬁcant relationship
between circulating NT4/5 and pain (n ¼ 78; P¼.012) (C). As the majority of markers did not have an association with pain, subsequent
analyses were not stratiﬁed by pelvic pain. There was no association between circulating BDNF and age (n ¼ 104; P¼.245) (F).
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SUPPLEMENTAL FIGURE 5
Effect of oral contraceptives and Lupron on circulating BDNF. In the
group of 25 women being treated for endometriosis, nine women
were on oral contraceptives (OCP) and 16 were on Lupron (16 of
25). There was no signiﬁcant difference (P¼.203) in the
concentration of BDNF between women on OCP and those on
Lupron (A), thus they were grouped together and called the
‘‘treated’’ group in all subsequent analyses. Whiskers on the box
plots represent the 10th and 90th percentiles, while the lower limit
of the box is the 25th percentile and the upper limit is the 75th
percentile. The line within the box is the median of the data.
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